These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25694534)

  • 21. Rab7b participation on the TLR4 (Toll-like receptor) endocytic pathway in Shiga toxin-associated Hemolytic Uremic Syndrome (HUS).
    Lafalla Manzano AF; Gil Lorenzo AF; Bocanegra V; Costantino VV; Cacciamani V; Benardon ME; Vallés PG
    Cytokine; 2019 Sep; 121():154732. PubMed ID: 31153054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome.
    Keepers TR; Gross LK; Obrig TG
    Infect Immun; 2007 Mar; 75(3):1229-36. PubMed ID: 17220320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease.
    Pradhan S; Pellino C; MacMaster K; Coyle D; Weiss AA
    Front Cell Infect Microbiol; 2016; 6():114. PubMed ID: 27747196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.
    Yamada S; Shimizu M; Kuroda M; Inoue N; Sugimoto N; Yachie A
    Clin Exp Nephrol; 2019 Apr; 23(4):544-550. PubMed ID: 30467800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
    Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
    J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutrophil Extracellular Traps Induced by Shiga Toxin and Lipopolysaccharide-Treated Platelets Exacerbate Endothelial Cell Damage.
    Landoni VI; Pittaluga JR; Carestia A; Castillo LA; Nebel MC; Martire-Greco D; Birnberg-Weiss F; Schattner M; Schierloh P; Fernández GC
    Front Cell Infect Microbiol; 2022; 12():897019. PubMed ID: 35811684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of thrombomodulin and tumor necrosis factor-alpha levels in patients with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection].
    Yamamoto T; Isokawa S; Miyata H; Yoshioka K
    Nihon Jinzo Gakkai Shi; 1999 Apr; 41(2):60-4. PubMed ID: 10361420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant thrombomodulin protects against LPS-induced acute respiratory distress syndrome via preservation of pulmonary endothelial glycocalyx.
    Suzuki K; Okada H; Takemura G; Takada C; Tomita H; Yano H; Muraki I; Zaikokuji R; Kuroda A; Fukuda H; Nishio A; Takashima S; Suzuki A; Miyazaki N; Fukuta T; Yamada N; Watanabe T; Doi T; Yoshida T; Kumada K; Ushikoshi H; Yoshida S; Ogura S
    Br J Pharmacol; 2020 Sep; 177(17):4021-4033. PubMed ID: 32497259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS).
    Mejias MP; Fernandez-Brando RJ; Ramos MV; Abrey-Recalde MJ; Zotta E; Meiss R; Palermo MS
    Curr Pharm Des; 2016; 22(34):5294-5299. PubMed ID: 27356777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
    Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
    Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant Thrombomodulin Modulates Murine Colitis Possibly via High-Mobility Group Box 1 Protein Inhibition.
    Ueda T; Higashiyama M; Narimatsu K; Yasutake Y; Kurihara C; Okada Y; Watanabe C; Yoshikawa K; Maruta K; Komoto S; Tomita K; Nagao S; Hokari R; Miura S
    Digestion; 2015; 92(2):108-19. PubMed ID: 26302768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Lou R; Tesh VL; Taylor FB
    Am J Nephrol; 2001; 21(5):420-5. PubMed ID: 11684808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.
    Ray PE; Liu XH
    Pediatr Nephrol; 2001 Oct; 16(10):823-39. PubMed ID: 11605791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of high mobility group box 1 in the pathogenesis of severe hemolytic uremic syndrome in a murine model.
    Maeda R; Kawasaki Y; Kume Y; Go H; Suyama K; Hosoya M
    Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1420-F1429. PubMed ID: 31482731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletion of Sphingosine Kinase 2 Attenuates Acute Kidney Injury in Mice with Hemolytic-Uremic Syndrome.
    Müller T; Krieg N; Lange-Polovinkin AI; Wissuwa B; Gräler MH; Dennhardt S; Coldewey SM
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome.
    Clayton F; Pysher TJ; Lou R; Kohan DE; Denkers ND; Tesh VL; Taylor FB; Siegler RL
    Am J Nephrol; 2005; 25(6):536-40. PubMed ID: 16179829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Tesh VL; Denkers ND; Taylor FB
    Pediatr Nephrol; 2002 Dec; 17(12):1053-8. PubMed ID: 12478357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.
    Siegler RL; Obrig TG; Pysher TJ; Tesh VL; Denkers ND; Taylor FB
    Pediatr Nephrol; 2003 Feb; 18(2):92-6. PubMed ID: 12579394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Ramos MV; Mejias MP; Sabbione F; Fernandez-Brando RJ; Santiago AP; Amaral MM; Exeni R; Trevani AS; Palermo MS
    J Innate Immun; 2016; 8(4):400-11. PubMed ID: 27230920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.